ReviewMethods (San Diego, Calif.)2022
CRISPR-Cas systems for diagnosing infectious diseases.
Review in Methods (San Diego, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Use of CRISPR-Cas Systems for Viral Detection: A Bibliometric Analysis and Systematic Review.Biosensors · 2025Pooled it
- Fast but accurate: a systematic review and meta-analysis on diagnostic performance of MRSA detection in clinical samples by using CRISPR-based rapid molecular methods.Frontiers in microbiology · 2025Pooled it
- Review
- Development of a CRISPR/dCas9-based membrane-assisted colorimetric assay for detection of high-risk HPV16 and HPV18: a proof-of-concept study.Molecular biology reports · 2026Article
- CRISPR/Cas12a2-Mediated Ultrasensitive Assay for Rapid Detection of H1N1 Influenza Virus RNA.ACS omega · 2026Article
- Development of a Highly Specific RPA/CRISPR-Cas13a Assay for Detection ofCurrent issues in molecular biology · 2026Article
- Review
- Trends of nucleic acid - based point-of-care diagnostics for infectious diseases.Journal of biological engineering · 2026Review
- CRISPR-Cas12a diagnostics forAnnals of medicine and surgery (2012) · 2026Article
- Establishment of a rapid Brucella detection method based on MCDA-CRISPR dual signal amplification system for reducing transfusion-transmitted diseases.Scientific reports · 2026Article
- One-pot recombinase polymerase amplification and CRISPR/Cas12a assay for Cryptococcus neoformans.Applied microbiology and biotechnology · 2026Article
- CRISPR-on-Chip for Point-of-Care Diagnostics.ACS nano · 2026Review
- A red/blue bicolor lateral flow immunoassay for simultaneous detection of two enteroviruses based on duplex RT-LAMP.Frontiers in microbiology · 2026Article
- Applications and Challenges of CRISPR-Cas Technology for the Detection of Antimicrobial Resistance Genes.Infection and drug resistance · 2026Review
- The application of CRISPR gene-editing technology in influenza prevention and control.Frontiers in genome editing · 2026Review
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- An overview of CRISPR-artificial intelligence theranostics: Current and emerging applications.Biomaterials translational · 2026Review
- Article
- Emerging threats of monkeypox virus in 2024: current insights and future directions.Future science OA · 2025Review
- CRISPR/Cas12a2 enables ultra-sensitive amplification-free RNA detection.Nucleic acids research · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel; thus, they are not available in resource-limited areas, for the purposes of large-scale screenings and in case of outbreaks and epidemics. Developing new, rapid, and affordable point-of-care diagnostic assays is urgently needed. This review focuses on CRISPR-based technologies and their perspectives to become platforms for point-of-care nucleic acid detection methods and as deployable diagnostic platforms that could help to identify and curb outbreaks and emerging epidemics. We describe the mechanisms and function of different classes and types of CRISPR-Cas systems, including pros and cons for developing molecular diagnostic tests and applications of each type to detect a wide range of infectious agents. Many Cas proteins (Cas3, Cas9, Cas12, Cas13, Cas14 etc.) have been leveraged to create highly accurate and sensitive diagnostic tools combined with technologies of signal amplification and fluorescent, potentiometric, colorimetric, lateral flow assay detection and other. In particular, the most advanced platforms -- SHERLOCK/v2, DETECTR, CARMEN or CRISPR-Chip -- enable detection of attomolar amounts of pathogenic nucleic acids with specificity comparable to that of PCR but with minimal technical settings. Further developing CRISPR-based diagnostic tools promises to dramatically transform molecular diagnostics, making them easily affordable and accessible virtually anywhere in the world. The burden of socially significant diseases, frequent outbreaks, recent epidemics (MERS, SARS and the ongoing COVID-19) and outbreaks of zoonotic viruses (African Swine Fever Virus etc.) urgently need the developing and distribution of express-diagnostic tools. Recently devised CRISPR-technologies represent the unprecedented opportunity to reshape epidemiological surveillance and molecular diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.